Rigel Pharmaceuticals, Incorporated

Halliburton Energy Services, Inc.

Simon Shaw

Vanessa Taylor

Somasekhar Bhamidipati

Rajinder Paul Singh

Esteban Masuda

Yan Chen

Donald G Payan

Ihab S Darwish

David Carroll

Dane A Goff

Yasumichi Hitoshi

Zhushou Luo

Jiaxin Yu

Rao Kolluri

Hui Li

Kin Tso

Thilo J Heckrodt

Rose Yen

Matt Duan

Dazhong Fan

Mark Irving

Lu Chou

Sarkiz D Issakani

Xiang Wu

Michel Joseph LeBlanc

Matthew Duncton

Mark Elliott Willis

Xiang Xu

Andreas Ellmauthaler

Arvinder Sran

Jack Maung

Jianing Huang

Nan Lin

Kyle Defrees

Hitoshi Yasumichi

David Sweeny

Chrystelle Lamagna

Lyuben Tsvetkov

Sarkiz Issakani

Dane Goff

Disclosed embodiments concern compounds according to Formula I In some embodiments, the compounds are useful as kinase inhibitors, such as interleukin receptor associated kinases (IRAK) inhibitors. Also disclosed are compositions comprising such inhibitors, and methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent a kinase-associated disease or condition, particularly an IRAK-associated disease or condition.

Tricyclic IRAK inhibitors

Disclosed herein are embodiments of a pyrazole compound according to formula I. Compositions comprising the compound, and a method for making the composition also are disclosed. The composition may comprise a carrier, such as a polymer and/or the composition may be a spray-dried formulation. Also disclosed is a method for using the compound and/or composition. The compound and/or composition may be useful to inhibit an IRAK protein and/or to ameliorate, treat and/or prevent an IRAK-associated disease or condition in a subject.

Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations

Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitor compounds and compositions comprising such compounds. The compounds may have a structure according to Formula I Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors

Disclosed herein are embodiments of a method for treating a disease or condition in a subject, comprising administering to the subject, a pyrazole compound according to formula I. The compound may be administered as a composition, such as a spray-dried formulation. The disease or condition may be hidradenitis suppurativa, or a lymphoid neoplasm, and may be chronic myeloid leukemia or chronic myelomonocytic leukemia.

Method for treating a disease or condition using a pyrazole compound or formulation thereof

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

Heterocyclic RIP1 kinase inhibitors

RIP1K inhibitors

RIP1 inhibitory compounds and methods for making and using the same

Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Amide compounds and method for making and using

A wellbore system includes a logging unit having a retrievable logging cable coupled to a downhole tool within a wellbore and a depth correlation unit in the downhole tool that provides current depth data for the wellbore through the retrievable logging cable for recording of a current depth by the logging unit. The wellbore system also includes a distributed acoustic sensing unit that includes a seismic processing unit and a seismic profiling unit connected to a separate optical cable of the retrievable logging cable having distributed acoustic sensing channels, wherein an assignment of the distributed acoustic sensing channels along the separate optical cable is determined by an offset distance between the current depth of a formation reference region within the wellbore and a previous reference depth of the formation reference region within the wellbore. A distributed acoustic sensing method is also included.

Retrievable fiber optic vertical seismic profiling data acquisition system with integrated logging tool for geophone-equivalent depth accuracy

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The compounds may have a structure according to Formula I  The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

Heterocyclic RIP1 inhibitory compounds

Growing community of inventors

Oakland, CA, United States of America

Simon Shaw